2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1363

Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome
Abstract Number: 745

Changes in Serum Albumin Levels Correlate Highly with Severity and Activity of SLE
Abstract Number: 2841

Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Abstract Number: 2032

Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Abstract Number: 527

Characterisation of the Antibody Response to a Citrullinated Peptide – Derived from the Porphyromonas Gingivalis Peptidyl Arginine Deiminase Enzyme – in Patients with Rheumatoid Arthritis
Abstract Number: 50

Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Abstract Number: 2523

Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Abstract Number: 1221

Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea
Abstract Number: 1090

Characteristics and Trajectories of Child Pain, Function, and Psychological Outcomes Associated with Conversion Disorder in Intensive Interdisciplinary Pediatric Pain Rehabilitation
Abstract Number: 2621

Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.
Abstract Number: 149

Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Abstract Number: 410

Characteristics of the Juvenile Systemic Sclerosis Cohort within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1779

Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology
Abstract Number: 1047

Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Abstract Number: 1177

Characterization of Different Phosphorylation Sites of Mcl-1 in Human Rheumatoid Arthritis Synovial Fibroblasts and Their Correlation with RA Pathogenesis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].